

Identification of Risks in Medical Laboratories

27.09.2021




DR REEMA BAHRI

**HEAD-CLINICAL BIOCHEMISTRY & QUALITY,
Batra Hospital & Medical Research Centre, New Delhi-110062
(NABL & NABH Assessor, Consultant-Quality Assurance,
Internal auditor and QMS trainer, CAP) MBBS., MD.**


Email: drreemabahri@rediffmail.com




Total Laboratory Process



Sources of Laboratory



Errors within the total testing process




The Medical Laboratory has a wide Risk footprint



Risk Definition

- Risk, essentially, is the potential for an error to occur that could lead to patient/staff harm.
- Risk can be estimated through a combination of the probability of occurrence of harm and the severity of that harm (ISO/IEC Guide 51, ISO 14971)


IQCP Development Process



Identify Risks

Fish Bone diagram - tribute to its creator

-helps RCA- identify, analyze, improve Quality issues




Fish Bone Analysis

Whole blood – unable to assess specimen integrity




IQCP ACT: Risk Assessment




Pareto Analysis – Quality Tool (TQM)


- Pareto Charts
- Trend Analysis:
- Pareto principle (80/20 rule) is that 80% of problems are produced by 20% of the possible causes
- Bar graph used to rank categories from most to least significant
- Helpful in displaying data presented for management review and action plans



Impact of preventive action on rejection rates in pre analytical phase



Risk Identification/Reduction Tools



- **Failure Modes and Effects Analysis (FMEA)** – systematic review that examines how failures can affect the instrument system or process; a “**bottom-up**” analysis.
- **FMECA**: “Failure Mode, Effects, and Criticality Analysis” estimates risk of failures & harm as part of analysis
- **FRACAS: Failure Reporting & Corrective Action System**- process by which failures are identified and analyzed so that corrective actions can be implemented.
- **FTA: Fault tree analysis** -systematic review of an instrument or system to identify potential sources of failure that starts by assuming a main system failure and determines what could cause it; a “**top-down**” analysis
- FTA and FMEA – analyze comprehensive top-down and bottom-up risk analysis.
- **FMEA/FTA** is conducted in clinical laboratory before an assay or an instrument system is implemented/purchased.
- It is important to include preanalytical (preexamination) and postanalytical (postexamination) process steps in an FMEA/FTA.

FRACAS and CAPA

- FRACAS is sometimes confused with Corrective and Preventive Action (CAPA).
- The difference for a manufacturer of FRACAS and CAPA – is the *FOCUS!!!*
- FRACAS, usually conducted by the Research and Development (R&D) department, focuses on design control measures. In a FRACAS conducted before release by a manufacturer, customer complaints do not exist, only *events*. These events could be harmful or could lead to customer complaints.
- CAPA, conducted by Operations Department and required by regulatory bodies, focuses on preventing the recurrence of nonconformities, which in some cases, can result in design control measures.



The 1% failure - catastrophe!!!



Risk Identification

Pre analytical



Analytical

Post analytical



IQCP ACT: Risk Assessment

Severity of harm

Probability		<i>Negligible</i>	<i>Minor</i>	<i>Serious</i>	<i>Critical</i>	<i>Catastrophic</i>
	Frequent	not ok	not ok	not ok	not ok	not ok
	Probable	ok	not ok	not ok	not ok	not ok
	Occasional	ok	ok	ok	not ok	not ok
	Remote	ok	ok	ok	ok	not ok
	Inconceivable	ok	ok	ok	ok	ok

ISO 14971

Frequent = once/week

Probable = once/month

Occasional = once/year

Remote = once every few years

Inconceivable = once in the life of the measuring system

Negligible = inconvenience or temporary discomfort

Minor = temporary injury or impairment not requiring professional medical intervention

Serious = injury or impairment requiring professional medical intervention

Critical = permanent impairment or life-threatening injury

Catastrophic = results in patient death

Risk Evaluation- Acceptability Chart (ISO 14971)

Severity

		Catastrophic: 4	Critical: 3	Moderate: 2	Marginal: 1
Probability	Frequent: 5	High - 20	High - 15	High - 10	Medium - 5
	Probable: 4	High - 16	High - 12	Serious - 8	Medium - 4
	Occasional: 3	High - 12	Serious - 9	Medium - 6	Low - 3
	Remote: 2	Serious - 8	Medium - 6	Medium - 4	Low - 2
	Improbable: 1	Medium - 4	Low - 3	Low - 2	Low - 1

The Risk need to be evaluated against criteria approved by the lab director !!!

EXAMPLE OF FRACAS

PRE ANALYTICAL ERRORS (PRE-EXAMINATION)

Steps/Type of error in which failure occurs	Failure/ Incident	Cause/RCA	Effect	Risk			CAPA
				Probability	Severity	Criticality	
Pre analytical Errors (pre-examination)	Sample Quality Compromised						
	Hemolyzed Sample (145/8285) 1.75%	Sample collection protocol not followed strictly	Repricks Patient harm TAT	5	2	10	<ul style="list-style-type: none"> • Sister on duty informed. • Repeat Sample requested and received. • Staff training • Roving Phlebos • Closed Collections – ECD
	Clotted Sample (92/8285) 1.11%	Sample collection protocol not followed strictly	Repricks Patient harm TAT	5	2	10	<ul style="list-style-type: none"> • Sister on duty informed. • Repeat Sample requested and received. • Staff training
	QNS Quantity not sufficient (4/8285) 0.04%	Sample collection protocol not followed strictly	Repricks Patient harm TAT	4	2	8	<ul style="list-style-type: none"> • Sister on duty informed. • Repeat Sample requested and received

EXAMPLE OF FRACAS

PRE ANALYTICAL ERROR (PRE-EXAMINATION)

Steps/Type of error in which failure occurs	Failure/Incident	Cause/RCA	Effect	Risk		CAPA
				Probability	Severity	Criticality
Pre analytical Errors (pre-examination)	Sample Quality Compromised					
	Lipemic (7/8285) 0.08%	Sample collection protocol not followed strictly	Comromised sample	4	2	8
	Wrong collection (5/8285) 0.06%	Sample collected from IV site or diluted Sample	Erroneous Results/ Repricks/ Patient harm	4	3	12

- Sister on duty informed.
- Repeat Sample
- Report on request

- Sister on duty informed.
- Repeat Sample requested and received.
- Staff retraining.

Risk Identification & CAPA




Hemolysis



Fibrin Mass



EDTA Under fill



Needle Stick Injury



Fibrin threads & poor barrier formation

CAPA: Shifting to closed collection system in IPDs & ICUs can reduce the burden of **pre-analytical errors**

REDUCE – DOUBLE PRICKS, SAMPLE CLOTS, INAPPROPRIATE SAMPLE VOLUMES, NSIs, SPILLAGE, etc.

PATIENT CARE AND SAFETY – OUR TOP PRIORITY



Gaps in Arterial blood collection



Sample flushed with
liquid Na Heparin

Diluti
onal
effect
of
liquid
hepari
n



Clott
ed
samp
le



Patient Sample Results

13/08/2019 08:37:14

Show

Status: ACCEPTED

13/08/2019 08:37:05

Sample Type: Arterial

Operator:

Patient: 19/16233

, BIRMO DEVI

Measured (37.0°C)

pH **7.55**
 pCO2 **42** mmHg
 pO2 **54** mmHg
 Na+ **133** mmol/L
 K+ **2.5** mmol/L
 Ca++ **4.93** mg/dL
 Glu **162** mg/dL
 Lac **2.2** mmol/L
 Hct **< 15** %

C = Incalculable

Patient Sample Results

13/08/2019 08:04:13

Show
History

Send

Print

Exit

Status: ACCEPTED

13/08/2019 06:35:44

Sample Type: Arterial

Operator:

Patient: BH634033

, PREM

Entered Data

Measured (37.0°C)

pH **7.25**
 pCO2 **50** mmHg
 pO2 **160** mmHg
 Na+ **< 100** mmol/L
 K+ **8.3** mmol/L
 Ca++ **1.28** mg/dL
 Glu **126** mg/dL
 Lac **1.6** mmol/L
 Hct **37** %

Derived Parameters

HCO3- **21.9** mmol/L
 TC02 **23.4** mmol/L
 BEecf **-5.3** mmol/L
 BE(B) **-5.5** mmol/L
 SO2c **99** %
 THbc **11.5** g/dL



ABG sample
taken in 5 mL
syringe

[illegible][illegible]

EXAMPLE OF FRACAS

PRE ANALYTICAL ERROR (PRE-EXAMINATION)

Steps/Type of error in which failure occurs	Failure/Incident	Cause/RCA	Effect	Risk			CAPA
				Probability	Severity	Criticality	
Pre analytical Errors (pre-examination)	Sample Quality Compromised						
	<ul style="list-style-type: none"> • Na is 118 in ABG • Discussed with clinician • Not acceptable 	<ul style="list-style-type: none"> • Dilutional • hyponatremia due to liquid Heparin in tuberculin (non-BD ABG syringe) • NON VALIDATED • (Wrong collection) 	<ul style="list-style-type: none"> • Patient discomfort • delay management 	5	3	15	<ul style="list-style-type: none"> • Repeat ABG sample received in BD syringe • RV Na: 132
	<ul style="list-style-type: none"> • O2 saturation 37 in ABG • Discussed with clinician • Not acceptable 	<ul style="list-style-type: none"> • Suspected VBG collection • (Wrong collection) 	<ul style="list-style-type: none"> • Patient discomfort • delay management 	5	3	15	<ul style="list-style-type: none"> • Repeat ABG sample received • RV O2: 97

BD Critical Care blood collection syringes

BD blood gas syringes

5.2.1 Sample Device

In most instances, the ideal collection device for arterial blood sampling is a 1- to 3-mL self-filling, plastic, disposable syringe, containing a small amount of an appropriate anticoagulant, such as lyophilized heparin. The choice of the type of heparin depends on the specific analytes to be determined and the method of analysis. Because ordinary heparin can bind to ionized calcium and other electrolytes that are often analyzed with blood gases and pH, special preparations of heparin are available, which virtually eliminate the interference from heparin binding of these electrolytes.



Blood Gas and pH Analysis and Related Measurements: Approved Guideline—Second Edition C46-A2 Vol. 29 No. 8

All BD ABG[®] syringes contain dry, lyophilized calcium balanced lithium heparin (improved electrolyte accuracy—particularly $\text{[Ca}^{2+}\text{]}$ and $\text{[Mg}^{2+}\text{]}$).

ABG CAPA - Validation Studies

- **ABG BD pre-heparinized syringes Vs 1ml tuberculin liquid heparinized syringes**
 - **Data analysis :** Inter syringe comparison
 - **Huge variations in electrolytes**
 - **False hyponatremia** - (Na⁺) > 10% diff - due to dilutional effect of liquid heparin
 - **False low Calcium** - since Heparin binds Calcium of blood unlike Lyophilized Heparin saturated with Calcium to avoid any Ca chelation from blood.
 - **Erratic results** - Other analytes ie. lactate, Hct, HCO₃⁻, TCO₂, Glucose, etc. ? dilutional effects
 - **Effect on pCO₂ and pO₂**- spuriously low in tuberculin syringes, due to the diffusion of gases from thin plastic wall of syringes, while with BD ABG syringe, due to the thick walled ABG syringe and rubber stopper to maintain the anaerobic state, the effect was not there
- ❖ **MEASURE, MONITOR, REDUCE OCCURRENCE**
- ❖ **Management Review : – Circulars – MD**
- ❖ **Trainings – BD – retrainings -Induction plan – Regular plan of all ICUs, wards, ER.**
- ❖ **ABG 10 clots/day to 0-1 Nil today**

The Covid-19 challenges!!!



[illegible]

Case 2: The Covid Stories...(2nd wave...)

ABG sample - Without label

Pre-analytical (*Risk!!*)

- **Sample quantity compromised?**
- **Without label ABG sample received in lab**
- **RCA- labelling Error/ Patient Identification**
- **Effect - Patient risk/safety**
- **CAPA- Sample run after discussion with ER Head**
- **RPAs– Internal/Third party**
- **Training Modules/Retraining**

(Lab Vaccination)
 (22/03/2023)
 2023 09:24

WILKINS BIOCHEMISTRY REQUISITION FORM

Patient's Name: _____ Age / Sex: _____ Phone no.: _____
 ID / OPD: _____ Date of sample collection: 9/6/21
 Patient's / Dr. Name: _____ Date & Time of sample collection: _____
 Receiving time at Lab: _____

Patient's Clinical Information: *Post-operative*

H. GLUCOSE (F)
 H. GLUCOSE (M)
 F. GLUCOSE (F)
 GGT WITH 100 G. GLUCOSE
 GGT WITH 75 G. GLUCOSE
 F. GLUCOSE 1 H. HEMATO CR. GLUCOSE

LIPID PROFILE
 1. CHOLESTEROL
 2. HDL CHOLESTEROL
 3. LDL CHOLESTEROL
 4. VLDL CHOLESTEROL
 5. TRIGLYCERIDE

CARDIAC PROFILE
 1. CPK
 2. CPK MB
 3. CPK TB
 4. CPK MB/CPK TB
 5. CPK MB/CPK TB
 6. CPK MB/CPK TB
 7. CPK MB/CPK TB
 8. CPK MB/CPK TB
 9. CPK MB/CPK TB
 10. CPK MB/CPK TB

URINE TEST
 1. CREATININE
 2. CREATININE CLEARANCE
 3. PROTEIN TOTAL
 4. CALCIUM
 5. MAGNESIUM
 6. PHOSPHORUS
 7. UREA
 8. GLUCOSE
 9. BILIRUBIN
 10. BILIRUBIN/CREATININE RATIO (SPOT)
 11. CALCIUM/CREATININE RATIO (SPOT)
 12. UREA/CREATININE RATIO (SPOT)
 13. BUN/CREATININE RATIO (SPOT)
 14. PROTEIN/CREATININE RATIO (SPOT)

BLOOD SALINITY
 1. BILIRUBIN
 2. BILIRUBIN/CREATININE RATIO (SPOT)
 3. CALCIUM/CREATININE RATIO (SPOT)
 4. UREA/CREATININE RATIO (SPOT)
 5. BUN/CREATININE RATIO (SPOT)
 6. PROTEIN/CREATININE RATIO (SPOT)

BLOOD SALINITY
 1. BILIRUBIN
 2. BILIRUBIN/CREATININE RATIO (SPOT)
 3. CALCIUM/CREATININE RATIO (SPOT)
 4. UREA/CREATININE RATIO (SPOT)
 5. BUN/CREATININE RATIO (SPOT)
 6. PROTEIN/CREATININE RATIO (SPOT)

OTHERS
 1. CPK MB
 2. CPK MB
 3. CPK MB
 4. CPK MB
 5. CPK MB
 6. CPK MB
 7. CPK MB
 8. CPK MB
 9. CPK MB
 10. CPK MB

BILIRUBIN PROFILE
 1. BILIRUBIN
 2. BILIRUBIN
 3. BILIRUBIN
 4. BILIRUBIN
 5. BILIRUBIN
 6. BILIRUBIN
 7. BILIRUBIN
 8. BILIRUBIN
 9. BILIRUBIN
 10. BILIRUBIN

BILIRUBIN PROFILE
 1. BILIRUBIN
 2. BILIRUBIN
 3. BILIRUBIN
 4. BILIRUBIN
 5. BILIRUBIN
 6. BILIRUBIN
 7. BILIRUBIN
 8. BILIRUBIN
 9. BILIRUBIN
 10. BILIRUBIN

BILIRUBIN PROFILE
 1. BILIRUBIN
 2. BILIRUBIN
 3. BILIRUBIN
 4. BILIRUBIN
 5. BILIRUBIN
 6. BILIRUBIN
 7. BILIRUBIN
 8. BILIRUBIN
 9. BILIRUBIN
 10. BILIRUBIN

BILIRUBIN PROFILE
 1. BILIRUBIN
 2. BILIRUBIN
 3. BILIRUBIN
 4. BILIRUBIN
 5. BILIRUBIN
 6. BILIRUBIN
 7. BILIRUBIN
 8. BILIRUBIN
 9. BILIRUBIN
 10. BILIRUBIN

BILIRUBIN PROFILE
 1. BILIRUBIN
 2. BILIRUBIN
 3. BILIRUBIN
 4. BILIRUBIN
 5. BILIRUBIN
 6. BILIRUBIN
 7. BILIRUBIN
 8. BILIRUBIN
 9. BILIRUBIN
 10. BILIRUBIN

BILIRUBIN PROFILE
 1. BILIRUBIN
 2. BILIRUBIN
 3. BILIRUBIN
 4. BILIRUBIN
 5. BILIRUBIN
 6. BILIRUBIN
 7. BILIRUBIN
 8. BILIRUBIN
 9. BILIRUBIN
 10. BILIRUBIN

BILIRUBIN PROFILE
 1. BILIRUBIN
 2. BILIRUBIN
 3. BILIRUBIN
 4. BILIRUBIN
 5. BILIRUBIN
 6. BILIRUBIN
 7. BILIRUBIN
 8. BILIRUBIN
 9. BILIRUBIN
 10. BILIRUBIN

BILIRUBIN PROFILE
 1. BILIRUBIN
 2. BILIRUBIN
 3. BILIRUBIN
 4. BILIRUBIN
 5. BILIRUBIN
 6. BILIRUBIN
 7. BILIRUBIN
 8. BILIRUBIN
 9. BILIRUBIN
 10. BILIRUBIN

BILIRUBIN PROFILE
 1. BILIRUBIN
 2. BILIRUBIN
 3. BILIRUBIN
 4. BILIRUBIN
 5. BILIRUBIN
 6. BILIRUBIN
 7. BILIRUBIN
 8. BILIRUBIN
 9. BILIRUBIN
 10. BILIRUBIN

BILIRUBIN PROFILE
 1. BILIRUBIN
 2. BILIRUBIN
 3. BILIRUBIN
 4. BILIRUBIN
 5. BILIRUBIN
 6. BILIRUBIN
 7. BILIRUBIN
 8. BILIRUBIN
 9. BILIRUBIN
 10. BILIRUBIN

BILIRUBIN PROFILE
 1. BILIRUBIN
 2. BILIRUBIN
 3. BILIRUBIN
 4. BILIRUBIN
 5. BILIRUBIN
 6. BILIRUBIN
 7. BILIRUBIN
 8. BILIRUBIN
 9. BILIRUBIN
 10. BILIRUBIN

BILIRUBIN PROFILE
 1. BILIRUBIN
 2. BILIRUBIN
 3. BILIRUBIN
 4. BILIRUBIN
 5. BILIRUBIN
 6. BILIRUBIN
 7. BILIRUBIN
 8. BILIRUBIN
 9. BILIRUBIN
 10. BILIRUBIN

BILIRUBIN PROFILE
 1. BILIRUBIN
 2. BILIRUBIN
 3. BILIRUBIN
 4. BILIRUBIN
 5. BILIRUBIN
 6. BILIRUBIN
 7. BILIRUBIN
 8. BILIRUBIN
 9. BILIRUBIN
 10. BILIRUBIN

BILIRUBIN PROFILE
 1. BILIRUBIN
 2. BILIRUBIN
 3. BILIRUBIN
 4. BILIRUBIN
 5. BILIRUBIN
 6. BILIRUBIN
 7. BILIRUBIN
 8. BILIRUBIN
 9. BILIRUBIN
 10. BILIRUBIN

BILIRUBIN PROFILE
 1. BILIRUBIN
 2. BILIRUBIN
 3. BILIRUBIN
 4. BILIRUBIN
 5. BILIRUBIN
 6. BILIRUBIN
 7. BILIRUBIN
 8. BILIRUBIN
 9. BILIRUBIN
 10. BILIRUBIN

BILIRUBIN PROFILE
 1. BILIRUBIN
 2. BILIRUBIN
 3. BILIRUBIN
 4. BILIRUBIN
 5. BILIRUBIN
 6. BILIRUBIN
 7. BILIRUBIN
 8. BILIRUBIN
 9. BILIRUBIN
 10. BILIRUBIN

BILIRUBIN PROFILE
 1. BILIRUBIN
 2. BILIRUBIN
 3. BILIRUBIN
 4. BILIRUBIN
 5. BILIRUBIN
 6. BILIRUBIN
 7. BILIRUBIN
 8. BILIRUBIN
 9. BILIRUBIN
 10. BILIRUBIN

BILIRUBIN PROFILE
 1. BILIRUBIN
 2. BILIRUBIN
 3. BILIRUBIN
 4. BILIRUBIN
 5. BILIRUBIN
 6. BILIRUBIN
 7. BILIRUBIN
 8. BILIRUBIN
 9. BILIRUBIN
 10. BILIRUBIN

BILIRUBIN PROFILE
 1. BILIRUBIN
 2. BILIRUBIN
 3. BILIRUBIN
 4. BILIRUBIN
 5. BILIRUBIN
 6. BILIRUBIN
 7. BILIRUBIN
 8. BILIRUBIN
 9. BILIRUBIN
 10. BILIRUBIN

BILIRUBIN PROFILE
 1. BILIRUBIN
 2. BILIRUBIN
 3. BILIRUBIN
 4. BILIRUBIN
 5. BILIRUBIN
 6. BILIRUBIN
 7. BILIRUBIN
 8. BILIRUBIN
 9. BILIRUBIN
 10. BILIRUBIN

BILIRUBIN PROFILE
 1. BILIRUBIN
 2. BILIRUBIN
 3. BILIRUBIN
 4. BILIRUBIN
 5. BILIRUBIN
 6. BILIRUBIN
 7. BILIRUBIN
 8. BILIRUBIN
 9. BILIRUBIN
 10. BILIRUBIN

BILIRUBIN PROFILE
 1. BILIRUBIN
 2. BILIRUBIN
 3. BILIRUBIN
 4. BILIRUBIN
 5. BILIRUBIN
 6. BILIRUBIN
 7. BILIRUBIN
 8. BILIRUBIN
 9. BILIRUBIN
 10. BILIRUBIN

EXAMPLE OF FRACAS

PRE ANALYTICAL ERROR (PRE-EXAMINATION) Case 3 : The Covid Stories...

Steps/Type of error in which failure occurs	Failure/Incident	Cause/RCA	Effect	Risk			CAPA
				Probability	Severity	Criticality	
Pre analytical Errors (pre-examination)	Sample Quality Compromised						
	<ul style="list-style-type: none"> Wrong report of patient detected by Delta checks CRP Day 1:180 Day 2 :24 	<ul style="list-style-type: none"> Labeling error due to overburden of staff in pandemic situation (Wrong identification) 	<ul style="list-style-type: none"> The Covid Story Staff shortage PPE Misleading information to clinician Provisional report uploaded 	4	3	12	<ul style="list-style-type: none"> Fresh sample collected & analyzed CRP Day 2 RV:380 Correlating clinically with patient's condition Final corrected report released

EXAMPLE OF FRACAS

PRE ANALYTICAL ERROR (PRE-EXAMINATION)

Steps/Type of error in which failure occurs	Failure/Incident	Cause/RCA	Effect	Risk			CAPA
				Probability	Severity	Criticality	
Pre analytical Errors (pre-examination)	Sample Quality Compromised						
	<ul style="list-style-type: none"> • K value 7.6, Phos- 8.2, • Ca- 8.0; • Not acceptable to clinician 	<ul style="list-style-type: none"> • Tight tourniquet application suspected • Incorrect report 	<ul style="list-style-type: none"> • Patient risk • Psuedo-hyperkalemia • Result uploading provisional report • Lab - clinical validation by lab staff 	4	3	12	<ul style="list-style-type: none"> • Fresh sample collected properly repeated from other arm after stopping dextrose drip for 2 mts. • Fresh sample taken and analyzed • K- 4 .7, • Phosphorus-3.4, • Ca - 8.5 • Training of nursing staff -IP

EXAMPLE OF FRACAS

PRE ANALYTICAL ERROR (PRE-EXAMINATION)

Steps/Type of error in which failure occurs	Failure/Incident	Cause/RCA	Effect	Risk			CAPA
				Probability	Severity	Criticality	
Pre analytical Errors (pre-examination)	Sample Quality Compromised						
	<ul style="list-style-type: none"> • K value >10, • Ca <2.0 • Not acceptable 	Suspected KCL mix up (Wrong collection)	RESULT HALTED BY LAB (NIL) RISK MITIGATED	4	2	8	<ul style="list-style-type: none"> • Fresh sample collected after stopping drip and analyzed • RV K 4.6 Ca 9.0 • clinically correlating • Report released
	<ul style="list-style-type: none"> • Na >200 (NaF) • ALP <5 (Low due to EDTA in NAF vial – chelating effect) • Not acceptable 	Serum analyte picked from Glucose vial, Wrong barcode generation (IT error-right click error)	RESULT HALTED BY LAB (NIL) RISK MITIGATED	3	2	6	<ul style="list-style-type: none"> • Repeat barcode generated for serum sample • Sample reanalyzed • Values ok • Report released

EXAMPLE OF FRACAS

PRE ANALYTICAL ERROR (PRE-EXAMINATION)


Steps/Type of error in which failure occurs	Failure/Incident	Cause/RCA	Effect	Risk			CAPA
				Probability	Severity	Criticality	
Pre analytical Errors (pre-examination)	Sample Quality Compromised						
	<ul style="list-style-type: none"> Na Value >200 Not acceptable 	<ul style="list-style-type: none"> Suspected Saline mix up (Wrong collection) 	Reprick	4	2	8	<ul style="list-style-type: none"> Fresh sample collected & analyzed RV 145 Acceptable

EXAMPLE OF FRACAS

ANALYTICAL ERROR (EXAMINATION)


Steps/Type of error in which failure occurs	Failure/Incident	Cause/RCA	Effect	Risk			CAPA
				Probability	Severity	Criticality	
Analytical Errors (Examination)	Sample Quality Compromised						
	<ul style="list-style-type: none"> • Frequent and Multiple random errors:1-3s QC failures • Observed in TP, Alb, Calcium etc. • Equipment Flag 3375. 	<ul style="list-style-type: none"> • Aspiration errors. • Gel admixture getting sipped • Gel found on sample probe • Observed gel on some random BD SST tubes, samples • RCA: BD gel melted during centrifugation. 	<ul style="list-style-type: none"> • Chaos • Redo work • Over cautious working • Staff under stress/ • TAT challenges!!! 	1 <i>(Improbable)</i>	3	3	<ul style="list-style-type: none"> • Complaint raised with company • BD vacutainer lot changed. • Changed probe. • Changed centrifugation speed from 4000rpm for 10mts to 3500rpm for 15mts.

Gel in Serum Sample





EXAMPLE OF FRACAS



Overview

Orders

Results

QC-Cal

Exceptions

Reagents

Supplies

System

Levey-Jennings graph

Assay: AlbG

Control lot: 26440


Comparison type: None

Control: BIORAD CC

Exp. date: 30.11.2020

Module: 1

Status: Enabled



Remarks:

- frequent QC failures? get administrative gutty reports
- observed get in problem a sample
- Approximation same in equipment. Application specialist called. Almost day
- of maintenance. did change of probe. changed probe
- not advised change spin & time of centrifugation. a costly time.
- transition is changed on 29/11/19
- sample reported by PC & LHC.

Date range: 01.10.2019 - 30.11.2019

Graph

Point

Time completed: 30.11.2019 / 22:41

Value: 4.1 g/dL

Exit

QC selection

QC summary

Print

Details...

F1

F2

F3

F4

F5

F6

F7

F8

Overview

Orders

Results

QC-Cal

Exceptions

Reagents

Supplies

System

Levey-Jennings graph

Assay: CaC

Control lot: 26440

Comparison type: None

Control: BIORAD CC

Exp. date: 30.11.2020

Module: 1

Status: Enabled


LEVEL Level 1 N 100
 MEAN 10.17500 SD 0.31250
 CONTROL RANGE 9.55000 - 10.80000

COMPARISON MEAN
 COMPARISON SD

VISIBLE DATE
 RANGE

12.11.2019 30.11.2019

+3 SD
 +2 SD
 +1 SD
 MEAN
 -1 SD
 -2 SD
 -3 SD



LEVEL Level 2 N 97
 MEAN 11.70000 SD 0.35000
 CONTROL RANGE 11.00000 - 12.40000

COMPARISON MEAN
 COMPARISON SD

VISIBLE DATE
 RANGE

15.11.2019 30.11.2019

+3 SD
 +2 SD
 +1 SD
 MEAN
 -1 SD
 -2 SD
 -3 SD



Handwritten notes:
 frequent gel gel outliers & gel alternative getting dropped
 LCA observed gel on probe on samples
 CAPA: hydration error in equipment found Application Specialist
 called. Advised change lot of Vacutainer. Change the probe
 (B): advised change the time of centrifugation, clotting time.
 vacutainer lot change and equilibrate change the lot

Date range:

01.10.2019 - 30.11.2019

Graph

Point

Time completed: 30.11.2019 / 22:43

Value: 10.5 mg/dL

Exit

QC selection

QC summary

Print

Details

F1

F2

F3

F4

F5

F6

ANALYTICAL ERROR (EXAMINATION)

EXAMPLE OF FRACAS

Steps/Type of error in which failure occurs	Failure/Incident	Cause/RCA	Effect	Risk			CAPA
	Sample Quality Compromised			Probability	Severity	Criticality	
Analytical Errors (Examination)							
	Multiple analyte QC failures (1/39688)	<ul style="list-style-type: none"> Poor feed water quality ? TDS250 RO Filtration failed Post filter TDS:7 VERY HIGH Acceptable Limits TDS <1 	<ul style="list-style-type: none"> All WORK HALTED!!! Wrong report released of one patient report UA 6.8, Chol 341, HDL-C 63, LDL-C 106, TG 892 Risk !!! 	1	4	4	<ul style="list-style-type: none"> All reports reviewed One report which was released was recalled Entire water pipeline of water supply to equipment was cleaned Equipment daily maintenance, QC rerun – ok Patient sample reanalyzed: UA - 7.3, CHOL 195, HDL-C 29, LDL-C 79, TG 531 Amended Report issued Internal protocol for feed water to lab - revised Water systems –Pipeline changed

EXAMPLE OF FRACAS

ANALYTICAL ERROR (EXAMINATION)

Steps/Type of error in which failure occurs	Failure/Incident	Cause/RCA	Effect	Risk			CAPA
				Probability	Severity	Criticality	
Analytical Errors (Examination)	Sample Quality Compromised						
	Ca value is 17.5 <i>Not acceptable!!!</i>	<ul style="list-style-type: none"> Fibrin picked by machine and error given was ignored by technician. Equipment Flagged 3375 missed by technician 	Mitigated -discussed with Clinician	3	4	12	<ul style="list-style-type: none"> Serum defibrinized Same sample rerun rerun Ca 8.5 CAPA: retraining of technical staff on error codes Lab protocol to inform supervisor/HOD/clinician

EXAMPLE OF FRACAS

POSTANALYTICAL ERROR (POSTEXAMINATION)

Steps/Type of error in which failure occurs	Failure/Incident	Cause/RCA	Effect	Risk		CAPA
				Probability	Severity	Criticality
Postanalytical Errors (Post-examination)	Sample Quality Compromised					
	•Wrong typed Vitamin B12 value 21.2 released	•Typographical error (Post dispatch error)	•Mitigated	3	2	6
						<ul style="list-style-type: none"> Report recalled Vit B12 115 retyped correctly Amended report issued

EXAMPLE OF FRACAS

POSTANALYTICAL ERROR (POSTEXAMINATION)

Steps/Type of error in which failure occurs	Failure/Incident	Cause/RCA	Effect	Risk			CAPA
				Probability	Severity	Criticality	
Postanalytical Errors (Post-examination)	Sample Quality Compromised						
	<ul style="list-style-type: none"> Wrong value of HbA1C typed 0.34 by typist 	<ul style="list-style-type: none"> Typographical error (Pre dispatch error) 	<ul style="list-style-type: none"> Mitigated 	3	2	6	<ul style="list-style-type: none"> HbA1C value 6.0, corrected during authentication
	<ul style="list-style-type: none"> Report typed without comments of Biological reference interval 	<ul style="list-style-type: none"> Typographical error (Pre dispatch error) 	<ul style="list-style-type: none"> Mitigated 	3	1	3	<ul style="list-style-type: none"> Report corrected during authentication Re training of typist

A Note on What Are and Are Not Failures


- Some failures occur at interfaces between the clinical laboratory and the clinician
- If a clinician makes an incorrect medical decision, but benefits from better information provided in a laboratory report, errors can be minimized
- Case 1
- 40 year male patient CKD, regular visitor for dialysis unit
- Lab Investigations: Urea : 109; Cr: 4.0; iPTH : 5250 pg/ml – vv high
- Lab advisory: Hyperparathyroidism , need for further evaluation to rule out PTH tumor
- Case discussed with Nephrologist: candidate for surgical parathyroidectomy!!!

A Note on What Are and Are Not Failures

- Case 2
 - Specimen: Pancreatic Juice/Fluid: For CEA, CA19.9, Amylase
 - CEA <0.5ng/ml; CA 19.9 < 2.0 U/ml; Amylase: 3.0 U/L
 - Cytology - acellular findings
 - D/D : Psuedocyst, Mucinocyst
 - So probable diagnosis by Lab report is Simple Hydatid Cyst

IQCPANIC?





REFERENCES

- **ISO 14971:2007 and 2012 International Organization for Standardization. Medical devices – Application of risk management to medical devices**
- **CLSI Guideline C24 – A3-Clinical and Laboratory Standards Institute. Statistical quality control for quantitative measurements procedures: principles and definitions. Approved guideline - 3rd ed. C24 – A3. Wayne, PA: Clinical and Laboratory Standards Institute, 2006.**
- **ISO 22367:2008 Medical Laboratories – Reduction of error through risk management and continual improvement.**
- **ISO 31000:2009 Risk management -- Principles and guidelines**
- **ISO Guide 73:2009**
- **CLSI Guideline EP18 - A2 Clinical and Laboratory Standards Institute (CLSI). Risk Management Techniques to identify and control laboratory error sources: Approved guideline - second edition.**
- **CLSI Guideline EP23 – A Clinical and Laboratory Standards Institute. Laboratory quality control based on risk management. Approved guideline - 1st edition. EP23 – A. Wayne, PA: Clinical and Laboratory Standards Institute, 2011.**
- **Risk management - Guidance for the implementation of ISO 31000**
- **ISO/IEC Guide 51:2014**

THE UNSUNG LAB HEROS!!!



Acknowledgements!!!



THANK YOU





Thank You

Any Questions pls...